Skip to main content
Menu Search & Directory

Clinical Trials

Healthy volunteers of all ages, races, and genders are needed to continue vaccine development at the Saint Louis University Center for Vaccine Development.

Participation in a vaccine study is voluntary and confidential. All study vaccines and tests are free of charge and volunteers receive compensation for time and travel. Participation involves completing a short online survey that includes some personal questions. Your participation is voluntary.

Join Our Database

A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents

Background 

The purpose of this study is to find out if an investigational vaccine called PXVX0317 is safe in people 12 to <65 years of age and also to predict whether it will work as a vaccine to prevent a person from getting sick from a virus called chikungunya virus that causes chikungunya disease. “Investigational” means that this vaccine is not approved by the US Food and Drug Administration (FDA). 

The chikungunya virus is a germ that causes a disease with a high fever and pain in many joints. The knees, elbows, wrists, ankles, and/or fingers are generally affected. In really bad cases, the joint pain can be severe and can last for a long time (months or even years). Chikungunya disease typically occurs in areas such as Africa, parts of Asia, South America, and the Caribbean. The virus is most often spread to a person by a mosquito bite that can result in illness and disease. The disease can affect travelers from the US who are visiting these areas that have mosquitoes with the virus, and since 2014 there have been local cases seen in Florida, Puerto Rico and US Virgin Islands. Vaccines are given to keep people from getting sick in the future if they are exposed to the virus. There are currently no FDA-approved vaccines to prevent chikungunya disease. 

Duration

About 3150 individuals will take part in the study which will be conducted in the US. Your participation in the study will last about 7 months, and you will be injected with either the PXVX0317 vaccine or a substitute mixture of salt and water with no drug added known as a “placebo."

Key Points

  • To participate, you must be between 12-65 years old.
  • Participation is strictly voluntary. 

Payment and Time Commitment

You will be paid for completed in-clinic and phone visits if you are enrolled in the study. You are considered to be “enrolled” in the study once you have been randomly assigned into a study group and receive your injection. You will be paid [$75.00] for the screening visit, [$75.00] for your vaccination visit, [$75.00] for your visits after the injection (3), [$25.00] for the scheduled phone visits (2), and [$100.00] for the final visit. 

To discuss volunteering, please contact us at: 
1-866-410-6333 (toll free) 
vaccine@slu.edu
Refer to study IRB # 17652   

COVAIL convalescent blood

We are looking for adult volunteers who were hospitalized for COVID-19.   

Key Points  

  • To participate you must be 18 years old or older
  • You must have been hospitalized for COVID-19 6 weeks to 4 months ago.  
  • You will be compensated $75 for this blood draw study.
  • IRB# 26646 
Chikungunya Vaccine Study

The purpose of this study is to find out if an investigational vaccine called PXVX0317 is safe in people 12 to <65 years of age and also to predict whether it will work as a vaccine to prevent a person from getting sick from a virus called chikungunya virus that causes chikungunya disease. Chikungunya disease typically occurs in areas such as Africa, parts of Asia, South America, and the Caribbean. The virus is most often spread to a person by a mosquito bite that can result in illness and disease. 

Key Points

  • The study will last about 7 months.  
  • You must be between 12-65 years old to participate.
  • You will be compensated $75 for clinic visits, $25 for the scheduled phone visits, and $100 for the final visit.
  • IRB # 17652 
Yellow Fever Vaccine Study

Yellow fever is a mosquito-borne disease due to a virus that causes a wide range of health problems, from mild symptoms to severe illness, including liver, kidney, and/or heart injury, and death. There is no specific treatment for yellow fever; however, medicines can be used to reduce the symptoms in seriously ill people. The most efficient method to avoid yellow fever is prevention by vaccination. 

Key Points 

  • The study will last about 5 years.  
  • You must be between 18-60 years old to participate.
  • You will be compensated $75 for each study visit and $25 for a safety telephone call.
  • IRB # 17632 
Gritstone COVID-19 Booster Trial

The purpose of this study is to test four investigational vaccines for the coronavirus that emerged in Wuhan, China in December 2019 that can cause serious respiratory infections. The study vaccine(s) you receive will depend on the Stage and Group in which you are enrolled. 

Key Points 

  • The study will last about 13 months.  
  • You must be 18 years old and older to participate.
  • You will be compensated $100.00 for each required vaccination), $75.00 for each clinic visit (6-12), and $25.00 for each phone call.  
  • IRB # 17622